Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Urinary Incontinence, Stress | 16 | 2019 | 196 | 4.050 |
Why?
|
Sex Reassignment Surgery | 6 | 2022 | 41 | 3.560 |
Why?
|
Suburethral Slings | 9 | 2016 | 75 | 2.190 |
Why?
|
Urologic Surgical Procedures | 10 | 2021 | 147 | 1.760 |
Why?
|
Transsexualism | 3 | 2021 | 34 | 1.440 |
Why?
|
Urethra | 6 | 2020 | 115 | 1.320 |
Why?
|
Urinary Bladder | 5 | 2022 | 246 | 1.300 |
Why?
|
Urodynamics | 8 | 2016 | 122 | 1.290 |
Why?
|
Pelvic Floor Disorders | 7 | 2021 | 55 | 1.280 |
Why?
|
Penile Prosthesis | 2 | 2019 | 24 | 1.250 |
Why?
|
Surgical Flaps | 5 | 2022 | 249 | 1.220 |
Why?
|
Vagina | 4 | 2022 | 173 | 1.070 |
Why?
|
Robotic Surgical Procedures | 2 | 2022 | 306 | 1.030 |
Why?
|
Urology | 3 | 2022 | 117 | 0.930 |
Why?
|
Urination | 3 | 2016 | 37 | 0.860 |
Why?
|
Urinary Bladder, Neurogenic | 2 | 2016 | 25 | 0.830 |
Why?
|
Prostheses and Implants | 6 | 2019 | 124 | 0.790 |
Why?
|
Sexual Health | 1 | 2022 | 17 | 0.780 |
Why?
|
Surgical Mesh | 3 | 2019 | 123 | 0.770 |
Why?
|
Penis | 3 | 2019 | 60 | 0.770 |
Why?
|
Prosthesis Implantation | 4 | 2012 | 126 | 0.660 |
Why?
|
Catastrophization | 1 | 2019 | 7 | 0.660 |
Why?
|
Penile Implantation | 1 | 2019 | 14 | 0.650 |
Why?
|
Urological Agents | 1 | 2018 | 5 | 0.650 |
Why?
|
Neuromuscular Agents | 2 | 2010 | 26 | 0.640 |
Why?
|
Botulinum Toxins, Type A | 2 | 2010 | 50 | 0.620 |
Why?
|
Pelvic Floor | 7 | 2022 | 85 | 0.620 |
Why?
|
Biocompatible Materials | 1 | 2018 | 198 | 0.570 |
Why?
|
Female | 41 | 2022 | 46202 | 0.570 |
Why?
|
Humans | 61 | 2022 | 89357 | 0.540 |
Why?
|
Urinary Incontinence | 5 | 2018 | 213 | 0.500 |
Why?
|
Patient Satisfaction | 6 | 2019 | 461 | 0.480 |
Why?
|
Surgeons | 4 | 2021 | 248 | 0.460 |
Why?
|
Postoperative Complications | 11 | 2022 | 2284 | 0.450 |
Why?
|
Urination Disorders | 2 | 2005 | 50 | 0.430 |
Why?
|
Laparoscopy | 1 | 2020 | 773 | 0.420 |
Why?
|
Prostatectomy | 5 | 2008 | 477 | 0.410 |
Why?
|
Minimally Invasive Surgical Procedures | 1 | 2014 | 253 | 0.400 |
Why?
|
Prospective Studies | 11 | 2016 | 4289 | 0.370 |
Why?
|
Fluoroscopy | 2 | 2021 | 123 | 0.360 |
Why?
|
Radiology | 3 | 2021 | 201 | 0.360 |
Why?
|
Terminology as Topic | 4 | 2012 | 221 | 0.350 |
Why?
|
Sex Reassignment Procedures | 2 | 2021 | 4 | 0.340 |
Why?
|
Quality of Life | 6 | 2018 | 1668 | 0.340 |
Why?
|
Surveys and Questionnaires | 7 | 2016 | 2624 | 0.330 |
Why?
|
Middle Aged | 24 | 2021 | 25974 | 0.330 |
Why?
|
Urinary Bladder, Overactive | 1 | 2010 | 90 | 0.320 |
Why?
|
Follow-Up Studies | 10 | 2014 | 3666 | 0.300 |
Why?
|
Adult | 19 | 2022 | 26607 | 0.300 |
Why?
|
Societies, Medical | 2 | 2022 | 575 | 0.300 |
Why?
|
Male | 24 | 2022 | 42411 | 0.300 |
Why?
|
Defecography | 3 | 2021 | 3 | 0.290 |
Why?
|
Defecation | 3 | 2021 | 23 | 0.290 |
Why?
|
Catheterization | 1 | 2008 | 237 | 0.280 |
Why?
|
Pelvic Organ Prolapse | 2 | 2022 | 154 | 0.270 |
Why?
|
Diagnostic Techniques, Urological | 2 | 2014 | 14 | 0.270 |
Why?
|
Lumbosacral Plexus | 1 | 2005 | 9 | 0.250 |
Why?
|
Time Factors | 8 | 2021 | 5338 | 0.250 |
Why?
|
Urinary Bladder Neck Obstruction | 1 | 2005 | 21 | 0.250 |
Why?
|
Electric Stimulation Therapy | 1 | 2005 | 46 | 0.240 |
Why?
|
Kidney Transplantation | 2 | 2016 | 850 | 0.240 |
Why?
|
Cough | 1 | 2004 | 55 | 0.240 |
Why?
|
Magnetic Resonance Imaging | 5 | 2021 | 3448 | 0.240 |
Why?
|
Retrospective Studies | 4 | 2022 | 9057 | 0.230 |
Why?
|
Consensus | 6 | 2021 | 356 | 0.230 |
Why?
|
Feasibility Studies | 3 | 2020 | 780 | 0.230 |
Why?
|
Treatment Outcome | 10 | 2021 | 8241 | 0.220 |
Why?
|
Aged | 16 | 2021 | 19165 | 0.220 |
Why?
|
Perineum | 1 | 2022 | 36 | 0.210 |
Why?
|
Health Services for Transgender Persons | 1 | 2021 | 2 | 0.200 |
Why?
|
Colorectal Surgery | 1 | 2021 | 22 | 0.190 |
Why?
|
Societies, Scientific | 1 | 2021 | 43 | 0.190 |
Why?
|
Urogenital Surgical Procedures | 2 | 2011 | 10 | 0.190 |
Why?
|
Transplants | 2 | 2011 | 41 | 0.180 |
Why?
|
Clitoris | 1 | 2020 | 4 | 0.180 |
Why?
|
Disorders of Sex Development | 1 | 2020 | 18 | 0.180 |
Why?
|
Peritoneum | 1 | 2020 | 57 | 0.170 |
Why?
|
Injections | 2 | 2018 | 116 | 0.170 |
Why?
|
Penile Erection | 1 | 2019 | 22 | 0.170 |
Why?
|
Transgender Persons | 1 | 2021 | 107 | 0.170 |
Why?
|
Operative Time | 1 | 2020 | 143 | 0.170 |
Why?
|
Blood Loss, Surgical | 1 | 2020 | 115 | 0.170 |
Why?
|
Constriction, Pathologic | 1 | 2020 | 217 | 0.160 |
Why?
|
Coitus | 1 | 2018 | 20 | 0.160 |
Why?
|
Free Tissue Flaps | 1 | 2019 | 49 | 0.160 |
Why?
|
Aged, 80 and over | 8 | 2015 | 6811 | 0.150 |
Why?
|
Models, Educational | 1 | 2017 | 49 | 0.150 |
Why?
|
Urinary Reservoirs, Continent | 2 | 2009 | 14 | 0.140 |
Why?
|
Hydrodynamics | 1 | 2016 | 19 | 0.140 |
Why?
|
Contraindications, Procedure | 1 | 2016 | 7 | 0.140 |
Why?
|
Length of Stay | 1 | 2020 | 736 | 0.130 |
Why?
|
Recurrence | 2 | 2010 | 1144 | 0.130 |
Why?
|
Pain | 1 | 2019 | 400 | 0.130 |
Why?
|
Delivery, Obstetric | 1 | 2016 | 118 | 0.130 |
Why?
|
Obesity | 1 | 2022 | 971 | 0.130 |
Why?
|
Equipment Design | 2 | 2014 | 417 | 0.130 |
Why?
|
Monitoring, Ambulatory | 1 | 2015 | 32 | 0.130 |
Why?
|
Simulation Training | 1 | 2017 | 97 | 0.130 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2016 | 312 | 0.130 |
Why?
|
Body Weight | 1 | 2016 | 452 | 0.130 |
Why?
|
Erectile Dysfunction | 3 | 2006 | 75 | 0.120 |
Why?
|
Young Adult | 3 | 2020 | 6312 | 0.120 |
Why?
|
Lower Urinary Tract Symptoms | 1 | 2015 | 67 | 0.120 |
Why?
|
Urinary Retention | 1 | 2014 | 42 | 0.120 |
Why?
|
Tissue Engineering | 1 | 2016 | 185 | 0.120 |
Why?
|
Gastrointestinal Tract | 1 | 2016 | 191 | 0.120 |
Why?
|
Education, Medical | 1 | 2017 | 243 | 0.110 |
Why?
|
Colon | 3 | 2021 | 510 | 0.110 |
Why?
|
Pregnancy | 2 | 2022 | 3018 | 0.110 |
Why?
|
Pregnancy Complications | 1 | 2016 | 345 | 0.110 |
Why?
|
Prostatic Neoplasms | 4 | 2006 | 1769 | 0.110 |
Why?
|
Computer Simulation | 1 | 2016 | 1097 | 0.100 |
Why?
|
Urologic Surgical Procedures, Male | 2 | 2009 | 14 | 0.100 |
Why?
|
Ultrasonography, Interventional | 1 | 2012 | 123 | 0.100 |
Why?
|
United States | 5 | 2021 | 6989 | 0.100 |
Why?
|
Anatomic Landmarks | 2 | 2021 | 30 | 0.100 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2007 | 171 | 0.100 |
Why?
|
Colostomy | 1 | 2011 | 13 | 0.100 |
Why?
|
Multiple Trauma | 1 | 2011 | 34 | 0.100 |
Why?
|
Urinary Diversion | 2 | 2004 | 42 | 0.090 |
Why?
|
Abdominal Injuries | 1 | 2011 | 46 | 0.090 |
Why?
|
Pelvic Bones | 1 | 2011 | 43 | 0.090 |
Why?
|
Anal Canal | 1 | 2011 | 88 | 0.090 |
Why?
|
Injections, Intramuscular | 1 | 2010 | 64 | 0.090 |
Why?
|
Gynecologic Surgical Procedures | 1 | 2012 | 148 | 0.090 |
Why?
|
Wounds, Nonpenetrating | 1 | 2011 | 113 | 0.090 |
Why?
|
Fractures, Bone | 1 | 2011 | 128 | 0.090 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2007 | 401 | 0.080 |
Why?
|
Prosthesis Design | 2 | 2007 | 298 | 0.080 |
Why?
|
Pelvis | 2 | 2006 | 96 | 0.080 |
Why?
|
Preoperative Care | 3 | 2008 | 396 | 0.080 |
Why?
|
Urinary Catheterization | 1 | 2008 | 36 | 0.080 |
Why?
|
Valsalva Maneuver | 1 | 2008 | 6 | 0.080 |
Why?
|
Surgical Instruments | 1 | 2008 | 57 | 0.080 |
Why?
|
Internship and Residency | 1 | 2017 | 1045 | 0.080 |
Why?
|
Pressure | 2 | 2008 | 165 | 0.080 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2006 | 72 | 0.070 |
Why?
|
Interleukin-2 | 2 | 1997 | 251 | 0.070 |
Why?
|
Prevalence | 2 | 2022 | 1243 | 0.070 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2006 | 94 | 0.070 |
Why?
|
Contrast Media | 2 | 2021 | 1091 | 0.070 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2006 | 69 | 0.060 |
Why?
|
Apomorphine | 1 | 2005 | 10 | 0.060 |
Why?
|
Dopamine Agonists | 1 | 2005 | 27 | 0.060 |
Why?
|
Polycystic Kidney Diseases | 1 | 2005 | 20 | 0.060 |
Why?
|
Skin, Artificial | 1 | 2004 | 8 | 0.060 |
Why?
|
Urinary Bladder Diseases | 1 | 2004 | 41 | 0.060 |
Why?
|
Severity of Illness Index | 1 | 2010 | 1840 | 0.060 |
Why?
|
Abdomen | 1 | 2004 | 122 | 0.060 |
Why?
|
Electrodes, Implanted | 1 | 2005 | 177 | 0.060 |
Why?
|
Alprostadil | 1 | 2003 | 25 | 0.060 |
Why?
|
Lymph Nodes | 1 | 2006 | 548 | 0.050 |
Why?
|
Carcinoma, Renal Cell | 2 | 1997 | 437 | 0.050 |
Why?
|
Gender Dysphoria | 1 | 2021 | 9 | 0.050 |
Why?
|
Gender Identity | 1 | 2021 | 53 | 0.050 |
Why?
|
Kidney Neoplasms | 2 | 1997 | 638 | 0.050 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2021 | 58 | 0.050 |
Why?
|
Interdisciplinary Communication | 1 | 2021 | 131 | 0.050 |
Why?
|
Patient Positioning | 1 | 2021 | 65 | 0.040 |
Why?
|
Rectum | 1 | 2021 | 148 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 2 | 2009 | 2661 | 0.040 |
Why?
|
Referral and Consultation | 1 | 2022 | 341 | 0.040 |
Why?
|
Radiography | 1 | 2000 | 809 | 0.040 |
Why?
|
Prostate-Specific Antigen | 1 | 2000 | 360 | 0.040 |
Why?
|
Patient Education as Topic | 1 | 2021 | 360 | 0.040 |
Why?
|
Reproducibility of Results | 1 | 2004 | 2758 | 0.040 |
Why?
|
Ultrasonography | 1 | 2000 | 712 | 0.040 |
Why?
|
Diabetes Mellitus | 1 | 2005 | 742 | 0.040 |
Why?
|
Adolescent | 1 | 2010 | 9263 | 0.040 |
Why?
|
Incidence | 1 | 2022 | 1595 | 0.040 |
Why?
|
Aging | 1 | 2022 | 718 | 0.040 |
Why?
|
Neoplasms, Multiple Primary | 1 | 1997 | 103 | 0.030 |
Why?
|
Self Report | 1 | 2017 | 297 | 0.030 |
Why?
|
Sexual Behavior | 1 | 2018 | 311 | 0.030 |
Why?
|
Catheters | 1 | 2015 | 76 | 0.030 |
Why?
|
Prazosin | 1 | 1995 | 10 | 0.030 |
Why?
|
Adrenergic alpha-Antagonists | 1 | 1995 | 31 | 0.030 |
Why?
|
Predictive Value of Tests | 3 | 2006 | 1723 | 0.030 |
Why?
|
Prostatic Hyperplasia | 1 | 1995 | 91 | 0.030 |
Why?
|
Algorithms | 1 | 2021 | 1877 | 0.030 |
Why?
|
Cystectomy | 2 | 2009 | 110 | 0.030 |
Why?
|
Attitude of Health Personnel | 1 | 2017 | 645 | 0.030 |
Why?
|
Colon, Sigmoid | 1 | 2009 | 6 | 0.020 |
Why?
|
Cecum | 1 | 2009 | 69 | 0.020 |
Why?
|
Wound Healing | 1 | 2011 | 359 | 0.020 |
Why?
|
Ileum | 1 | 2009 | 160 | 0.020 |
Why?
|
Risk Factors | 1 | 2018 | 5499 | 0.020 |
Why?
|
Regression Analysis | 1 | 2009 | 590 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2008 | 306 | 0.020 |
Why?
|
Postoperative Period | 1 | 2008 | 302 | 0.020 |
Why?
|
Injections, Subcutaneous | 2 | 1997 | 125 | 0.020 |
Why?
|
Odds Ratio | 1 | 2009 | 683 | 0.020 |
Why?
|
Subtraction Technique | 1 | 2006 | 132 | 0.020 |
Why?
|
Hydrostatic Pressure | 1 | 2004 | 4 | 0.020 |
Why?
|
Delayed-Action Preparations | 1 | 2005 | 110 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2006 | 502 | 0.010 |
Why?
|
Treatment Failure | 1 | 2004 | 287 | 0.010 |
Why?
|
Ultrasonography, Doppler, Color | 1 | 2003 | 38 | 0.010 |
Why?
|
Patient Compliance | 1 | 2005 | 231 | 0.010 |
Why?
|
Testosterone | 1 | 2005 | 276 | 0.010 |
Why?
|
Blood Flow Velocity | 1 | 2003 | 200 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2009 | 1242 | 0.010 |
Why?
|
Reoperation | 1 | 2004 | 599 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2006 | 2018 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2005 | 1719 | 0.010 |
Why?
|
Prognosis | 1 | 2006 | 3783 | 0.010 |
Why?
|
Contraindications | 1 | 1996 | 70 | 0.010 |
Why?
|
Vinblastine | 1 | 1996 | 108 | 0.010 |
Why?
|
Methotrexate | 1 | 1996 | 250 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2000 | 2015 | 0.010 |
Why?
|
Doxorubicin | 1 | 1996 | 301 | 0.010 |
Why?
|
Chemotherapy, Adjuvant | 1 | 1996 | 487 | 0.010 |
Why?
|
Remission Induction | 1 | 1997 | 740 | 0.010 |
Why?
|
Multicenter Studies as Topic | 1 | 1995 | 155 | 0.010 |
Why?
|
Cisplatin | 1 | 1996 | 618 | 0.010 |
Why?
|
Sex Factors | 1 | 1996 | 1066 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 1996 | 1719 | 0.010 |
Why?
|
Survival Rate | 1 | 1997 | 1901 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 1996 | 2566 | 0.000 |
Why?
|